Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Aspen Aerogels Inc (ASPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Aspen Aerogels Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Aspen Aerogels Inc trades at $5.11 (market cap $425.99M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 10.5× Aspen Aerogels Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | ASPN | |
|---|---|---|
Market Cap | $4.49B | $425.99M |
Sector | Health | Technology |
52-Week High | $28.06 | $8.82 |
52-Week Low | $20.06 | $2.57 |
Enterprise Value | $3.69B | $380.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ASPN trades at $5.47, down 1.97% today, with a bearish technical signal despite bullish moving averages. The company reported a Q1 2026 net loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility after an incident. Cash flow improved in 2026 projections, with net cash flow narrowing to -$17 million from -$63 million in 2025.
Outlook remains challenging with persistent losses and negative margins, but analyst sentiment is strongly bullish (83% buy ratings). Key risks include execution on facility restarts, EV demand volatility, and cash burn. The stock's investment case hinges on operational turnaround and revenue growth acceleration amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →
